Search

Your search keyword '"Creaney, Jenette"' showing total 157 results

Search Constraints

Start Over You searched for: Author "Creaney, Jenette" Remove constraint Author: "Creaney, Jenette" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
157 results on '"Creaney, Jenette"'

Search Results

2. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

5. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

6. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

7. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

8. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

9. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

10. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

11. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

12. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

13. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

14. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

15. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

17. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.

19. New Markers for Management of Mesothelioma.

23. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology

27. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.

28. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.

30. How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.

36. What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination.

37. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.

41. Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1‐3 tyrosine kinase inhibitor anticancer therapy.

43. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.

44. Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia.

46. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.

47. Hyaluronic acid in viscous malignant mesothelioma pleural effusion.

48. Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

50. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.

Catalog

Books, media, physical & digital resources